Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indi-Blade: Induction Ipilimumab and Nivolumab for Bladder Sparing
NCT05200988Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Mar 2022
- Primary completion
- Sep 2025
- Countries
- 1
- Sponsor
- Netherlands Cancer Institute
- Modality
- Monoclonal Antibodies
- Drugs
- ipilimumabnivolumab
- Conditions
- Urothelial Bladder Cancer (UBC)
01
Overview
Phase 2, open-label trial of ipilimumab and nivolumab in Urothelial Bladder Cancer (UBC), sponsored by Netherlands Cancer Institute. Started Mar 2022; status: active, not recruiting.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Adult patients with cT2-4aN0-2 urothelial bladder cancer seeking bladder preservation or medically unfit for surgery, with adequate organ function and no prior pelvic radiation or immunotherapy.
04
Registry description
This is a single-armed, multicenter, non-blinded phase 2 study to assess efficacy of induction ipilimumab + nivolumab followed by chemoradiation to spare the bladder in urothelial bladder cancer.
Beyond the preview
Go deeper on NCT05200988.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200988.